BioSpace News Archive

Taiho Oncology today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib).*

Checkpoint Surgical, a privately held U.S. based medical device company with proprietary neurostimulation technology for nerve protection and repair, announced today the completion of an $8.8 million preferred series capital raise led by Mutual Capital Partners, a Cleveland based venture fund investing in rapidly growing, post-revenue technology businesses.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) announced today that the company has reached an agreement with the Securities and Exchange Commission (SEC) to fully resolve an investigation into forward-looking financial goals and related disclosures by Walgreen Co. (Walgreens).

BioConnect is pleased to announce that Julia Webb, former VP of Sales and Marketing at VoiceVault, will be joining BioConnect as Vice President, Alliances and reporting to CEO and Chairman, Rob Douglas.

Agreement creates academic health system focused on patient-centered care, innovation and clinical excellence

Endo International plc (NASDAQ: ENDP) will announce its third-quarter 2018 financial results on November 8, 2018 and members of its senior management team will host a conference call and webcast at 8:00 a.m. ET before the U.S. financial markets open.

Yesterday, Datwyler, a leading supplier of customized sealing solutions to global biotech and pharmaceutical markets, celebrated the official opening and start of production of its new facility with First Line standard in Middletown, Delaware.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional patient registry, called Tracing the Effect of the MC4R Pathway in Obesity (TEMPO).

Training will take place through the “Rensselaer Health INCITE Pipeline”

clonoSEQ is a first-in-class NGS assay and the first and only FDA-cleared MRD assay for any lymphoid cancer